Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new drug last month and ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

U.S. drugmaker Pfizer PFE.N is going “all in” to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the JPMorgan ...

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

“The point is that, according to the researchers’ argument, deprivation lies on a path of cause and effect going from having ADHD to having a lower life expectancy, and adjusting for deprivation could ...